Overview
GW823093C For The Treatment Of Type 2 Diabetes Mellitus
Status:
Terminated
Terminated
Trial end date:
2006-11-25
2006-11-25
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study was designed to find dose response and as extension in treatment of GW823093C.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
GlaxoSmithKline
Criteria
Inclusion criteria:- Type 2 diabetes mellitus.
- Managed by diet therapy or receiving treatment with oral anti-diabetic monotherapy
(excluding TZD (Thiazolidinediones))
Exclusion criteria:
- Patients who have metabolic disease judged by investigator as a clinically
significance
- Serious cardiovascular disease or serious hepatic disease